Mérieux Participations 3 Fund

https://www.merieux-partners.com

8 January 2020 - Mérieux Equity Partners announces the closing of the fundraising for Mérieux Participations 3, new investment fund dedicated to Growth Capital and Buy-Out within the Healthcare and Nutrition sectors, oversubscribed at € 377 million. Dedicated to supporting profitable and fast-growing companies in the healthcare and nutrition sectors, Mérieux Participations 3 fund was launched with the support of Institut Mérieux as a sponsor and an initial hard cap of € 350 million. In December 2019, the new vehicle closed at € 377 million, with commitments from leading European Family Holdings and Institutions. As part of its development, Mérieux Equity Partners expanded its investment team in 2019 with the appointment of Marie-Justine Lecomte and Romain Chevrillon as Associates within the Growth Capital and Buy-Out team and now employs 16 staff members in Lyon, Paris and Boston, of which 8 resources dedicated to Growth Capital & Buy-Out. To date, Mérieux Participations 3 has completed seven transactions in France and Europe in support of fastgrowing industrial companies, including four majority deals. In 2019, Mérieux Equity Partners invested in Addmedica – a French specialty pharmaceutical company engaged in rare diseases, Doc Generici – Italy’s largest independent generic pharmaceutical company – and more recently Mabtech, a Swedish life science company specialized in immune monitoring. *

	Start	2019-12-31 closing, final
	Group	Mérieux (Group)
	Predecessor	Mérieux Equity Partners S.A.S.
	Industry	venture capital
	Industry 2	healthcare

	Region	Lyon
	Country	France
	City	n. a. Lyon
		Address record changed: 2020-12-02

Basic data	Employees	n. a.

		* Document for ï¿½About Sectionï¿½: Mérieux Equity Partners S.A.S.. (1/8/20). "Press Release: Mérieux Equity Partners Successfully Completes the Fundraising of Mérieux Participations 3". Lyon.

		Record changed: 2021-02-21